Skip to content

Author

Scott E. Woodman

We have 3 of 28 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

46 TKI Resistance is Associated with Immune Dysfunction in ccRCC

Abstract Background Antiangiogenic tyrosine kinase inhibitors (TKIs) have become a cornerstone in the management of clear cell renal cell carcinoma (ccRCC) as monotherapy or in combination with immune checkpoint blockades (ICB). However, TKIs produce limited long-term durability even in combination with ICBs, indicatin...

Xian-De Liu, Hong-Chao He, Jing-Jing Liu et al. · 0 citations
Jul 2026

Abstract A027: Leveraging genomic copy-number complexity in uveal melanoma to drive novel therapeutic development

It is demonstrated that uveal melanoma progression reflects an integrated CN-transcriptional ecosystem extending beyond chromosome 3 loss, with cytoband-level genomic evolution shaping malignant fitness and therapeutic response.

Johnathon L. Rose, Sanjana Srinivasan, A. Cooper et al. · 0 citations
Jul 2026

Abstract A053: Specific cancer cell and immune features mediate atezolizumab-regimen clinical benefit in anaplastic thyroid cancer (ATC) independent of BRAF or RAS oncogenic status

Specific differentiation and immune activation features are associated with longer OS, whereas mesenchymal, hypoxic, and proliferative programs are associated with shorter OS, whereas mesenchymal, hypoxic, and proliferative programs are associated with shorter OS.

Brian McKinley, Hai-Feng Zhu, Rare Tumor Initiative Team et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.